Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Can COVID-19 cause severe neutropenia?
López-Pereira P, Iturrate I, de La Cámara R, Cardeñoso L, Alegre A, Aguado B. López-Pereira P, et al. Among authors: alegre a. Clin Case Rep. 2020 Oct 26;8(12):3349-3351. doi: 10.1002/ccr3.3369. eCollection 2020 Dec. Clin Case Rep. 2020. PMID: 33363932 Free PMC article.
Bortezomib is an efficient agent in plasma cell leukemias.
Esparís-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J, Schenkein D, Pandiella A, San Miguel JF. Esparís-Ogando A, et al. Among authors: alegre a. Int J Cancer. 2005 Apr 20;114(4):665-7. doi: 10.1002/ijc.20793. Int J Cancer. 2005. PMID: 15609327
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients.
Alegre A, Aguado B, Giraldo P, Ríos E, Cánovas A, Ibáñez Á, Castillo I, Hernández MT, Oriol A, Palomera L, Rodríguez JN, García FL, Calvo JM, Martínez-Chamorro C, de la Serna J, Lahuerta JJ. Alegre A, et al. Int J Hematol. 2011 Mar;93(3):351-360. doi: 10.1007/s12185-011-0785-z. Epub 2011 Mar 1. Int J Hematol. 2011. PMID: 21360065 Clinical Trial.
Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.
Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, Mateos MV, Sureda A, Martinez-Chamorro C, Cibeira MT, Aguado B, Knight R, Rosettani B. Alegre A, et al. Leuk Lymphoma. 2012 Sep;53(9):1714-21. doi: 10.3109/10428194.2012.662643. Epub 2012 Mar 1. Leuk Lymphoma. 2012. PMID: 22292853 Clinical Trial.
Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP).
Alegre A, Benzo G, Alonso R, Martínez-López J, Jimenez-Ubieto A, Cuéllar C, Askari E, Prieto E, Aláez C, Aguado B, Velasco A, Krsnik I, Bocanegra A, Llorente L, Muñoz-Linares C, Morales A, Giménez E, Iglesias R, Martínez-Chamorro C, Alonso A, Jiménez-Montes C, Blanchard MJ; Grupo GM-GM. Alegre A, et al. Oncol Ther. 2023 Mar;11(1):83-96. doi: 10.1007/s40487-022-00212-5. Epub 2022 Dec 12. Oncol Ther. 2023. PMID: 36509945 Free PMC article.
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study.
García-Suárez J, de la Cruz J, Cedillo Á, Llamas P, Duarte R, Jiménez-Yuste V, Hernández-Rivas JÁ, Gil-Manso R, Kwon M, Sánchez-Godoy P, Martínez-Barranco P, Colás-Lahuerta B, Herrera P, Benito-Parra L, Alegre A, Velasco A, Matilla A, Aláez-Usón MC, Martos-Martínez R, Martínez-Chamorro C, Susana-Quiroz K, Del Campo JF, de la Fuente A, Herráez R, Pascual A, Gómez E, Pérez-Oteyza J, Ruiz E, Alonso A, González-Medina J, Martín-Buitrago LN, Canales M, González-Gascón I, Vicente-Ayuso MC, Valenciano S, Roa MG, Monteliu PE, López-Jiménez J, Escobar CE, Ortiz-Martín J, Diez-Martin JL, Martinez-Lopez J; Asociación Madrileña de Hematología y Hemoterapia (AMHH). García-Suárez J, et al. Among authors: alegre a. J Hematol Oncol. 2020 Oct 8;13(1):133. doi: 10.1186/s13045-020-00970-7. J Hematol Oncol. 2020. PMID: 33032660 Free PMC article.
Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature.
Lecumberri R, Krsnik I, Askari E, Sirvent M, González-Pérez MS, Escalante F, Pradillo V, Tamariz LE, Cánovas V, Alegre A, Gironella M, González-García ME, Infante MS, Lakhwani S, Martínez-Bilbao C, Dourdil V, Ramírez-Payer Á, Sarrá J, Cibeira MT. Lecumberri R, et al. Among authors: alegre a. Amyloid. 2020 Sep;27(3):163-167. doi: 10.1080/13506129.2020.1730791. Epub 2020 Feb 28. Amyloid. 2020. PMID: 32106714 Clinical Trial.
191 results